ROTH Capital Partners Acts as Joint Book-Running Manager for RedHill Biopharma Ltd. (Nasdaq:RDHL) in its
$14.4 Million Follow-On

For more information please contact:

Investment Banking
John Chambers
Vice-Chairman and
Head of Healthcare Investment Banking
(646) 358-1901
jchambers@roth.com

Michael Margolis, R.Ph.
Managing Director
(646) 358-1902
mmargolis@roth.com

Warren Dunnavant II
Senior Vice President
(646) 358-1903
wdunnavant@roth.com

Equity Capital Markets
Aaron Gurewitz
Head of Equity
Capital Markets
(949) 720-5703

agurewitz@roth.com

Nazan Akdeniz
Senior Vice President
(949) 720-5740

nakdeniz@roth.com

Lou Ellis
Senior Vice President
(949) 720-5739

lellis@roth.com

Transaction Information

On February 13th, RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) a biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, closed an underwritten public offering of its common stock. Including the full exercise of the over-allotment option, the Company sold an aggregate of 1,150,000 American Depository Shares, each representing ten ordinary shares of RedHill. The shares were sold at the public offering price of $12.50 per share, bringing the aggregate gross proceeds from the offering to approximately $14.4 million.

 

ROTH Capital Partners acted as joint book-running manager for the offering. 

 

About RedHill Biopharma Ltd.

RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) is an emerging Israeli biopharmaceutical company focused on the development and acquisition of late clinical-stage, proprietary, orally-administered drugs for the treatment of inflammatory and gastrointestinal (GI) diseases, including gastrointestinal cancers. RedHill is currently conducting 3 Phase III studies, in parallel, with 3 of its leading GI drugs: RHB-104 for Crohn's disease, RHB-105 for treatment of H. pylori infection and BEKINDA™ for gastroenteritis and gastritis, with top-line results expected from the RHB-105 and BEKINDA™ studies in Q2/2015 and Q4/2015 respectively. RedHill has filed marketing applications for 2 of its drugs, RIZAPORT™ for migraines (in the U.S. and Europe) and BEKINDA™ for oncology support (in Europe). RedHill's current pipeline of proprietary products includes: (i) RHB-105- an oral combination therapy for the treatment of Helicobacter pylori infection, with an ongoing first Phase III study; (ii) RHB-104- an oral combination therapy for the treatment of Crohn's disease, with an ongoing first Phase III study; (iii) BEKINDA™ (RHB-102)- a once-daily oral pill formulation of ondansetron with a Phase III study in the U.S. for acute gastroenteritis and gastritis and a European marketing application for chemotherapy and radiotherapy-induced nausea and vomiting submitted in December 2014; (iv) RHB-106- an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals, Ltd.; (v) MESUPRON® - a Phase II-stage uPA inhibitor, administered by oral capsule, targeting gastrointestinal and other solid tumor cancers; (vi) RP101- currently subject to an option-to-acquire by RedHill, RP101 is a Phase II-stage Hsp27 inhibitor, administered by oral tablet, targeting pancreatic and other gastrointestinal cancers; (vii) RIZAPORT™ (RHB-103)- an oral thin film formulation of rizatriptan for acute migraines with a U.S. NDA currently under discussions with the FDA and a European marketing application submitted in October 2014; and (viii) RHB-101- a once-daily oral pill formulation of the cardio drug carvedilol(Source: RedHill Biopharma Ltd. | March 4, 2015)

 

About ROTH Capital Partners

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access. Headquartered in Newport Beach, CA, ROTH is privately-held and employee owned, and maintains offices throughout the U.S. and Hong Kong. For more information on ROTH, please visit www.roth.com

 

The material, information and  facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2015.